Metabolic reprogramming in malignant A375 cells treated with a ruthenium (II) complex: insights from GCxGC-TOF/MS metabolomics.

ABSTRACT:

Introduction

Melanoma is an aggressive form of cancer characterised by its high metabolic adaptability that contributes to drug resistance. To this end, ruthenium complexes have emerged as a promising class of compounds in the discovery of cancer drugs due to their unique chemical properties and potential to overcome some of the limitations of conventional chemotherapy. In our previous study, we synthesised, characterised, and performed cytotoxicity tests of a ruthenium (II) complex (GA113) against the malignant A375 melanoma cell line. Our previous findings revealed favourable cytotoxicity, with an IC₅₀ value of 8.76 µM which formed the basis current study.

Objective

Elucidate the metabolic mechanism of GA113 in malignant A753 melanoma cells.

Method

A two-

SUBMITTER: Adu-Amankwaah F 

PROVIDER: S-EPMC11825624 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature